Loading...
•
Mar 31, 2024
Fate Therapeutics Q1 2024 Earnings Report
Reported business highlights and financial results.
Key Takeaways
Fate Therapeutics reported its Q1 2024 financial results, including revenue of $1.9 million and cash, cash equivalents, and investments of $391.1 million. The company also made progress across three key areas of clinical focus with FT819, FT522 and FT825 programs.
First lupus patient was treated with FT819 CAR T-cell product candidate in Phase 1 autoimmunity study; future clinical development of FT819 to focus exclusively on autoimmune disease.
Enrollment was initiated with FT522 CAR NK Cell product candidate in conditioning-free treatment arm of Phase 1 B Cell Lymphoma Study.
First patient was treated with FT825 / ONO-8250 CAR T-cell product candidate in Phase 1 solid tumor study.
The company has $391 million in cash, cash equivalents, and investments.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Fate Therapeutics plans to expand clinical development in autoimmunity with its off-the-shelf FT819 and FT522 programs.